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The human immunodeficiency virus, type 1 (HIV-1)-encoded
Rev protein is essential for the expression of late viral mRNAs.
Rev forms a large organized multimeric protein-protein com-
plex on the Rev response element of these viral mRNA species
and transports them from the nucleus to the cytoplasm, exploit-
ing the CRM1-mediated cellular machinery. Here we report the
selection of a nanobody, derived from a llama heavy-chain only
antibody, that efficiently blocks the assembly of Rev multimers.
The nanobody inhibits HIV-1 replication in cells and speci-
fically suppresses the Rev-dependent expression of partially
spliced and unsplicedHIV-1 RNA. InHIV-susceptible cells, this
nanobody thushas potential as an effective anti-HIVagent using
genetic immunization strategies. Its binding site wasmapped to
Rev residues Lys-20 and Tyr-23 located in the N-terminal-heli-
cal multimerization domain. In the presence of this nanobody,
weobserved an accumulationof dimericRev species, supporting
a head-to-head/tail-to-tail molecular model for Rev assembly.
The results indicate that the oligomeric assembly of Rev follows
an ordered stepwise process and identify a new epitope within
Rev that could guide strategies for thedevelopment of novelHIV
inhibitors.
Nuclear export of viral mRNA is critical for the life cycle of
the human immunodeficiency virus (HIV).2 Fully spliced viral
mRNA is exported to the cytoplasm of the infected cell through
cellular mechanisms. However, in contrast to cellular systems,
HIV uses a sophisticated molecular machinery to transport
unspliced and partially spliced forms of its viral mRNA. The
nuclear export of these late viral messengers is required for
both the expression of late viral genes and packaging of
genomic RNA and is mediated by the HIV-encoded regulatory
protein Rev (1). The viral Rev protein forms a multimeric
complex on a secondary structured RNA element (the Rev
response element (RRE)) present in all unspliced and par-
tially spliced mRNAs (2–4) and exploits the CRM1-medi-
ated cellular machinery to transport these RNAs from the
nucleus to the cytoplasm (5–7).
Rev is a small protein of 116 amino acid residues. Under
steady state conditions, Rev localizes mainly to the nucleoli of
cells (8). However, different functional elements cause Rev to
continuously shuttle between the nucleus and the cytoplasm
(9–11). A short stretch of basic amino acids characterized by 10
arginine residues serves both as a nuclear localization signal for
the nuclear import of Rev and as an RNA-binding domain dur-
ing the export of RNA-Rev complexes (4). This arginine-rich
region is flanked on both sides by sequences that contribute to
the oligomerization of Rev on the RRE. Its strong tendency to
oligomerize has hampered the structure determination of
Rev by x-ray crystallography or NMR spectroscopy. However,
circular dichroism, nuclear magnetic resonance, and Raman
spectroscopy studies strongly suggest that the oligomerization
domains and the nuclear localization signal are components of
a helix-turn-helix motif (12–14). A leucine-rich nuclear export
signal (15) binds the cellular export receptor CRM1 and medi-
ates nuclear export (5–7, 16, 56). Disruption of the nuclear
export signal results in a dominant negative mutant (e.g.
RevM10) that retains nucleolar localization and RRE binding
but is defective in nuclear export because it does not engage
with CRM1 (17). On the other hand, compounds disrupting the
Rev-CRM1 interaction and hence nuclear export of Rev have
been described (18–20).
One important aspect of the Rev function is its requirement
for multimerization (21, 22). Oligomerization of Rev has been
shown in vitro and in cell culture (21, 23–25). Initial binding to
the high affinity Rev binding site of the RRE (stem-loop IIB) is
followed by multimerization of Rev along the RRE template via
a combination of cooperative hydrophobic protein-protein
interactions and electrostatic protein-RNA interactions lead-
ing to the further coating of stem IIA and stem I of the RRE (3,
22, 26). Compared with the monomer, the Rev multimer forms
a higher affinity complex with the RRE, indicating that the oli-
gomer Revmolecules can expose their RNA-binding domain to
alternative binding sites on the RRE (26, 28). According to the
current model for the intermolecular interactions between Rev
monomers on the RRE, Rev cooperatively assembles one mol-
ecule at a time via a series of symmetrical tail-to-tail and head-
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to-head protein-protein interactions (24, 27). However,
although it is essential for Rev function, the mechanistic role of
multimerization in the HIV replication has remained uncer-
tain. The progress of Rev assembly on the RRE may determine
the threshold to achieve a functional Rev response. Indeed,
there is a strong correlation between the affinity of the Rev
multimer for the RRE and efficiency of RNA export (26). Upon
reaching threshold levels of Rev, its multimerization on RRE
thus acts as a “molecular rheostat” that triggers the export and
expression of viral mRNAs encoding late gene products
(21, 22, 29).
In this study, we selected a molecule that specifically targets
the N-terminal multimerization domain of Rev. We took
advantage of the distinguishing feature of Camelidae that in
addition to conventional antibodies also produce smaller fully
functional antibodies solely composed of homodimeric heavy
chains (30). Nanobodies derived from these heavy-chain only
antibodies are minimally sized, highly soluble single domain
antibody fragments (31). Therefore, we have immunized a
llama with recombinant HIV-1 Rev protein and performed a
phage display screen for the variable domain repertoire of the
heavy-chain only antibodies that bind to Rev. From a dozen
nanomolar affinity Rev binders, we identified one nanobody
that blocks the multimerization of Rev and inhibits HIV-1 rep-
lication. It is the first known molecule directed against the Rev
N-terminal -helical multimerization domain. The use of this
nanobody also allowed us to support the molecular model for
concerted assembly of Rev multimers to a stepwise head-to-
head/tail-to-tail mechanism.
EXPERIMENTAL PROCEDURES
NanobodyGeneration, Selection, Expression, andPurification—
Llama immunizations, phage display construction, and
nanobody purifications were performed according to earlier
described protocols (32). One llama (Lama glama) was immu-
nizedwith 2mg of purified recombinantHIV-Rev over a period
of 6 weeks. The immunization, library construction, and nano-
body selection have been performed following standard proce-
dures according toConrath et al. (33), and a nanobody library in
pHen4 (32) of 3.7 107 independent clones was established.
Recombinant HIV-Rev-specific phages were recovered by
incubating recombinant HIV-Rev-coated wells with 100 mM
triethylamine, pH 11.0, for 10 min. The eluate containing the
phages was neutralized with Tris-HCl, pH 6.8, and added to
freshly grown TG1 cells. The HIV-Rev-coated wells were then
washed once with Tris-HCl, pH 6.8, and several times with
phosphate-buffered saline. Finally, freshly grown TG1 cells
were added to the wells to recover the non-eluted phages. After
two and three rounds of selection, individual colonies were
screened for the expression of HIV-specific nanobodies: Max-
isorb 96-well plates were coated overnight at 4 °C with 1 g/ml
purified recombinant HIV-Rev in sodium bicarbonate buffer,
pH 8.2. Residual protein-binding sites in the wells were blocked
for 2 h at room temperature with 2% milk in phosphate-buff-
ered saline. Detection of antigen-bound nanobodies was
performed with a mouse anti-hemagglutinin-decapeptide tag
(clone 16B12, Babco). Subsequent detection of the mouse anti-
tag antibodies was done with an alkaline phosphatase anti-
mouse IgG conjugate (Sigma). The absorption at 405 nm was
measured 15–30 min after adding the enzyme substrate p-ni-
trophenyl phosphate. Finally, all selected nanobody genes were
cloned in a pHEN6 vector for expression with a His tag in Esch-
erichia coli (33).
Cell Culture, Transfections, and Plasmids—Prokaryotic and
eukaryotic expression vectors were constructed using standard
molecular cloning techniques. pRev-GFP expresses the Rev
protein fused to the green fluorescent protein, and pNb-mKO
produces fusion proteins of nanobody with monomeric Kus-
abira Orange. HeLa, human epithelial cells, and human embry-
onal kidney 293T cells were maintained using standard proce-
dures. For transfection of plasmid DNA in HeLa, cells were
plated onto glass bottom microwell dishes (MatTek corpora-
tion) at 0.1 106 cells/plate and cultured until 50% confluent.
Then cells were washed with phosphate-buffered saline and
transfected with plasmid DNA using SuperFect transfection
reagent (Qiagen, Valencia, CA) according to the manufacturer’s
manual and incubated overnight. 293T cells were cultured in
microwell dishes until 50% confluence and transfected by the
calcium phosphate coprecipitation technique. For the virus
expression experiments, typically 0.5 g of pNL4-3 and different
amounts of pcDNA3.1-Nb- or pcDNA3.1-Dronpa-expressing
plasmids were used. pBKS DNA was added to each transfection
mixture so that in every transfection equal amounts of DNAwere
transfected. Virus expression was analyzed by measuring the
virus-associated core antigen (p24) in the supernatants of trans-
fected cells by an enzyme-linked immunosorbent assay (GE
Healthcare).
The NL4-3 molecular clone has been described previously
(34). NL-Nb190 and NL-Nb163 were generated by subcloning
the nanobody sequence into the BlpI-XhoI site of p83-10
(35). The resulting plasmids were obtained by replacing the
EcoRI-XhoI fragment from NL4-3 with the EcoRI-XhoI frag-
ment from p83-10 containing the nanobody sequences.
NLRev()RRE()CTE() was from B. Felber and G. Pavlakis.
Microscopy and Fluorescence Recovery after Photobleaching—
Transfected HeLa cells were imaged with an ArrayScan HCS
Reader (Thermo Scientific Cellomics) or a laser-scanning SP5
confocal microscope (Leica Microsystems) equipped with an
AF 6000 microscope and an Acousto optical beam splitter,
using an HCX plan apochromat 63 (numerical aperture 1.2)
water immersionobjectivemagnification.Enhancedgreen fluo-
rescent protein was monitored with the argon laser using the
488-nm line for excitation, and emission was detected between
492 and 558 nm.Monomeric Kusabira Orange fluorescent pro-
tein (mKO) was imaged using the DPSS 561-nm laser for exci-
tation, and emission was detected between 570 and 670 nm.
Fluorescence recovery after photobleaching studies were
performed by obtaining a series of 20 prebleach images of a
nucleolus at 5% Acousto optical tunable filter laser setting, fol-
lowed by a single 0.39 s bleach iteration at full laser power of a 1
m wide circle in the nucleolus. Subsequent post-bleach
images were acquired at 5% Acousto optical tunable filter with
the following time scheme: 20 images every 0.39 s, 20 images
every 1 s, and 15–55 images every 10 s. Data were background-
subtracted, bleach-corrected, and normalized according to
the method described (36). Half-times of recovery were
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obtained by fitting the recovery curves employing GraphPad
Prism (GraphPad Software, Inc.).
Protein Expression and Purification—pET29b() and
pET21b() constructs encoding, respectively, the Rev pro-
tein and fusion proteins ECFP-Rev, EYFP-Rev, ECFP-EYFP,
free ECFP, and free EYFP were transformed in E. coli
BL21(DE3) and expressed by a 3.5-h induction with 1 mM
isopropyl 1-thio--D-galactopyranoside. Cells were lysed
using the SLM Amino French pressure cell press (Beun-
DeRonde), and the proteins were purified via Ni2-nitrilo-
triacetic acid affinity chromatography. For immunization of
the llama, the Rev protein was further purified by anion
exchange chromatography (GE Healthcare).
Rev Multimerization Assay—To evaluate the effect of the
nanobodies on the Rev multimerization by fluorescence reso-
nance energy transfer (FRET), nanobody concentrations were
mixed (in a 96-well plate in 100l of phosphate-buffered saline)
with 0.1 M ECFP-Rev and 0.2 M EYFP-Rev either prior to or
following the assembly of Rev multimers. A sample with only
ECFP-Rev andEYFP-Revwas used as positive control for FRET,
whereas the combination of free ECFP plus EYFP-Rev was used
as negative control. After a 30-min incubation, the FRET per-
centage was determined using a spectrofluorometer (Safire2,
Tecan). Hence, emission was measured at 480 5 nm (C) and
530 5 nm (F) after excitation with 430 5 nm and at 530 5
nm (Y) after excitation with 490 5
nm. The relative FRET efficiency
was then calculated as follows. The
total FRET signal (F) was first cor-
rected for the “bleed-through” of
the donor ECFP (i.e. 44% of C) and
the “direct excitation” of the accep-
tor EYFP (i.e. 5% of Y), resulting
in the “real FRET”W,
W  F  0.44  C  0.05  B
(Eq. 1)
The FRET efficiency (E) is then





where  is the ratio between the
quantum yields of acceptor and
donor (i.e. 1.53). The relative FRET
percentage was obtained by ex-
pressing E relative to the FRET effi-
ciency of both the positive control
(100%) and the negative control
(0%).
Nothern Blot Analysis—mRNA
was extracted using the Oligotex
Direct mRNA kit (Qiagen). After
contaminating DNA was digested
using RNase-free DNase I (Invitro-
gen), the mRNA was denatured by
heating to 50 °C in glyoxal load dye
and separated by agarose electrophoresis under denaturing
conditions. mRNA was blotted using the NorthernMax-Gly
system (Ambion) according to themanufacturer’s manual. The
RNA probe spanning exon 7 from the BamHI to the BglII site
(nucleotides 8475–9056) of the NL4-3 genome was produced
by in vitro transcription from T7 primer PCR products.
Quantitative Reverse Transcription-PCR—Two days after
transfection, total mRNA from cells was extracted using the
OligotexDirectmRNAkit (Qiagen) followed byDNAdigestion
using RNase-freeDNase I (Invitrogen). DNase I-treatedmRNA
was used to generate cDNA along with Thermoscript reverse
transcriptase (Invitrogen) and oligo(dT)20. Quantitative re-
verse transcription-PCR for unspliced and multiply spliced
HIV mRNA was performed according to a protocol described
earlier (37) that we adapted slightly. For unspliced mRNA, 0.2
mM primers GAG1 and SK431 and 0.2 mM FAM-BHQ1 fluo-
rescent probe GAG3was used. For multiply splicedmRNA, 0.2
mM primers mf83 and mf84 and 0.2 mM FAM-BHQ1 fluores-
cent probe ks2-tq was used. Control reactions omitted
reverse transcriptase, and the number of cDNA copies was
determined using the HIV-1NL4-3 molecular clone or the
pTat/Rev DNA as standards. pTat/Rev represents partial
sequence (exons 4 and 7) of HIV-1 multiply spliced RNA
encoding Tat and Rev proteins. Results are expressed as the
FIGURE 1. Selection of Rev multimerization-inhibiting nanobodies. A, FRET for ECFP-Rev incubated
with EYFP-Rev and suitable negative controls. As a positive control, the FRET efficiency of an ECFP-EYFP
fusion protein was measured. The FRET efficiency from the ECFP-Rev/EYFP-Rev mix was inhibited by
recombinant unlabeled wild-type Rev protein. Results are mean S.E. (error bars), with n 3. B, effect of
the selected Rev-binding nanobodies on the Rev multimerization as measured by FRET. The graph shows
the percentage of FRET relative to the ECFP-Rev/EYFP-Rev mixture without nanobody added. The control
nanobody Nb163, cloned from a llama that was not immunized with Rev, was included as a negative
control. C, amino acid sequence of Nb190. The hypervariable regions are shown in red, green, and blue.
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number of copies of unspliced HIV mRNA per copy of mul-
tiply spliced RNA.
Mobility Shift Assays—High affinity IIB hairpin RRE labeled
with Alexa Fluor 633 was purchased from Sigma. RRE RNA
transcripts were prepared by a T7 in vitro transcription
(DuraScribe T7 Transcription Kit, Epicenter) and purified by
electrophoresis on a 6% polyacylamide gel. These RREs contain
2-fluorine-modified UTP and CTP to make them resistant to
degradation. The transcripts where then labeled with Alexa
Fluor 647 by an Ulysis Nucleic Acid Labeling Kit (Molecular
Probes). Binding reactions of Rev to RNA were performed in
buffer containing 20 mMTris-HCl (pH 8.0), 100 mMNaCl, 10
mM dithiothreitol with 0.1 mg/ml bakers’ yeast tRNA. Typi-
cally, either 5 nM IIB RRE and 100 nM Rev protein or 3 nM
RRE, 60 nM Rev, and 300 nM Nb190 or Nb163 were used. The
samples were incubated for 20 min at room temperature and
then run on a 6% polyacrylamide gel for 1 h. The bands were
visualized and quantified using an Ettan DIGE Imager (GE
Healthcare).
RESULTS
Identification of Nanobodies That
Bind Rev and Inhibit Multimeri-
zation—A llama (L. glama) was
immunized with 2 mg of purified
recombinant HIV-1 Rev protein
over a period of 6 weeks. The vari-
able domain repertoire of the heavy-
chain only antibodies from this
llama was then expressed in a phage
display library containing 3.7 107
independent clones. In order to
select Rev-specific phages, the
phage display library was panned on
immobilized Rev protein. After
three rounds of selection, individual
colonies were expressed in E. coli
and confirmed for binding to
recombinant Rev. Twelve different
nanobodies interacting with recom-
binant Rev were selected. To iden-
tify those nanobodies that selec-
tively block the multimerization of
Rev,we designed an in vitromultim-
erization assay based on FRET. In
this assay, Rev fused to cyan fluores-
cent protein (ECFP-Rev) was incu-
batedwith a Rev fusion of the yellow
fluorescent protein (EYFP-Rev).
Multimerization of Rev brings the
fused ECFP and EYFP labels in close
proximity, resulting in an effective
FRET efficiency of about 20% (Fig.
1A). The addition of excess unla-
beled Rev protein to the ECFP-Rev/
EYFP-Rev mix reduced the FRET
signal below 5% because it interca-
lates between the labeled Rev mole-
cules, thus increasing the distance
between ECFP and EYFP. One nanobody (Nb190) drastically
reduced the FRET signal from the ECFP-Rev/EYFP-Rev mix
(Fig. 1, B and C), indicating inhibition of Rev protein-protein
interaction.
Nb190DisassemblesMultimers of HIV-1 Rev—In ourmultim-
erization assay, Nb190 specifically reduced the FRET. It
remained unclear, however, if the nanobody, besides disrupting
the Rev-Rev interaction, also interferes with the Rev-RRE inter-
action. Therefore, gel shift experiments of Rev binding to the
high affinity IIB hairpin of RRE were performed (Fig. 2A). The
IIB stem-loop of RRE binds one single Rev monomer only (38).
In contrast to the control nanobodyNb163 that was cloned from
a llama not immunized with Rev (Fig. 2A, lane 7), the addition of
increasing amounts ofNb190 caused a reduction of themobility of
the IIB-Rev complex (Fig. 2A, lanes 3–6). This result confirms the
dose-dependent binding of the Nb190 to this Rev-RRE complex
withoutdisrupting theprotein-RNAinteraction.Nb190per sedoes
not interact with the IIB stem-loop of the RRE (Fig. 2A, lane 8).
FIGURE 2. Nb190 blocks the HIV Rev multimerization in vitro. A, effect of Nb190 on the Rev-RRE interaction.
Gel mobility shifts of labeled high affinity stem IIB RRE RNA in complex with Rev were performed in the
presence of increasing amounts of Nb190 (lanes 3–6; 0.02, 0.1, 0.5, and 2.5M, respectively). Bands correspond-
ing to free high affinity binding stem IIB RRE (lane 1), IIB-Rev (lane 2), and IIB-Rev-Nb190 complexes (lanes 4–6)
are indicated. Nb163 (lane 7) was included as negative control. B, effect of Nb190 on the organization of the
Rev-RREassembly.Gelmobility shift analysis ofmultimeric Revbinding to fluorescently labeled full-lengthRRE,
containing 2-fluorine-modified UTP and CTP, in the presence or absence of Nb190. The supershift of the
Rev-RRE complex in the presence of Nb190 is indicative of a ternary complex. M, monomeric; Di, dimeric; Tri,
trimeric; Tetr, tetrameric; Penta, pentameric. C, quantification of the ribonucleoprotein Rev-RRE species in gel
mobility shift experiments from B. Bands corresponding to the sum of free RRE plus monomeric Rev-RRE
(	dimeric), dimeric Rev-RRE (dimeric), and the sumof tri-, tetra-, andpentameric Rev-RRE complexes (
dimeric)
were quantified and expressed as a percentage of total RRE. Results are mean  S.E. (error bars) from four
independent experiments, p	 0.01 for
dimeric, and p	 0.005 for dimeric.
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Nb190 Accumulates Dimers of Rev
on the RRE—Efficient Rev function
requires the formation of a large
organized Rev-RRE ribonucleopro-
tein complex in which a Rev homo-
multimer assembles on the RRE
RNA (21, 26). To verify whether
Nb190 also blocks the multimeriza-
tion of Rev on the RRE, we assessed
the effect of Nb190 on the organiza-
tion of the Rev-RRE assembly by gel
retardation experiments. Fluores-
cently labeled full-length RRE, con-
taining 2-fluorine-modified UTP
and CTP tomake it resistant to deg-
radation, was produced by in vitro
transcription. Wild-type Rev forms
higher order multimeric com-
plexes on this RRE (Fig. 2B, lane 2)
(3). In the presence of Nb190, we
consistently observed reduced
amounts of higher order Rev-RRE
complexes while the species con-
taining dimeric Rev accumulated
(Fig. 2B, lane 3; quantified in Fig.
2C). It thus appears that Nb190 dis-
rupts higher order multimeric Rev
complexes along this RRE, result-
ing in a dimeric Rev phenotype on
the RNA.
Nb190 Is an IntrabodyThat Induces
aMultimerization-impairedRevPhe-
notype in Cells—Next, we investi-
gated whether Nb190 interacts with
Rev in living cells using confocal
fluorescence microscopy (Fig. 3).
For these experiments, we fused Rev
to GFP, and the nanobodies were
fused to the orange-colored mKO.
In agreement with earlier observa-
tions, transiently expressed Rev-
GFP primarily localized to the
nucleoli of HeLa cells (10, 11). In
these cells, Nb190-mKO was found
both in the nucleus and in the cyto-
plasm, and it distributed evenly over
both cellular compartments, as did
Nb163-mKO.However, when co-ex-
pressed, Rev-GFP and Nb190-mKO
both redistributed and co-localized
in the cytoplasm, in contrast to con-
trol experiments with Nb163-mKO.
Upon inhibition of the nuclear
export by leptomycin B, a redistri-
bution of both Rev-GFP and Nb190-
mKO to the nucleoli was observed
(supplemental Fig. S1), suggesting
active shuttling of the complex.
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Similarly, Nb190-mKO and RevM10-GFP demonstrated nucle-
olar co-localization (Fig. 3). Taken together, these data indicate
that Nb190 is an intrabody that binds Rev within the different
relevant cellular compartments and that it does not drastically
prohibit the shuttling of Rev between the nucleus and the cyto-
plasm of the cell. Most importantly, our nanobody provokes a
cellular redistribution of Rev that is very similar to the distribu-
tion caused by mutations that impair the multimerization of
Rev. Specifically, the RevV16D (24) and RevM4 (Y23D/S25D/
N26L) (17, 39) multimerization-deficient mutants display a
comparable diffuse cytoplasmic distribution in the absence of
Nb190. Interestingly,Nb190-mKOco-localizedwith theRevV16D
mutant but not with the multimerization-deficient RevM4
mutant, pointing toward a possible role of theTyr23–Asn26 seg-
ment of Rev in the recognition by Nb190.
Nb190 Interacts with Lys-20 and Tyr-23 in the N-terminal
-Helix of Rev—To further map the epitope in more detail, we
constructed Y23D, S25D, and N26L single Rev mutants and
investigated their interactionwithNb190 in living cells (Fig. 4A).
The Y23D and S25D mutations triggered a cytoplasmic Rev
localization, whereas RevN26L-GFP remained nucleolar. The
Y23D mutation per se was sufficient to inhibit the Rev-GFP/
Nb190-mKO co-localization in cells, suggesting a significant
role of Tyr-23 in the interaction with Nb190. We next con-
structed a series of alanine scan mutants in this region and
investigated the co-localization of Nb190 with these Rev
mutants in living cells (Fig. 4B). Per se, all of these Rev alanine
mutants localized to the cytoplasm of the cell, in contrast to
wild-type Rev, which is found in the nucleoli. Nb190-mKO still
co-localized with both the K20A and Y23A single mutants;
however, it did not interact any longer with the K20A/Y23A
double mutant. To confirm the contribution of each of these
single point mutations to the loss of interaction by the double
mutant, fluorescence recovery after photobleaching experi-
ments were performed (Fig. 4, C and D). For these interaction
studies, we used the nuclear export-deficient RevM10, which
remains nucleolar upon binding with Nb190 (Fig. 3). Cells
were transfected with RevM10-GFP, RevM10K20A-GFP, or
RevM10Y23A-GFP together with an Nb190-mKO-expressing
construct (Fig. 4C). Photobleaching of Nb190-mKO when
bound to RevM10-GFP in the nucleolus is followed by a slow
recovery with a half-recovery time of 102 s, which indicates
strong interaction between the two proteins. In contrast, the
recovery of Nb190-mKO when bound to RevM10K20A or
RevM10Y23A is much faster, with half-recoveries of 12 and
20 s, respectively. These results show that both K20A and
Y23A mutations have a drastic effect on the binding with
Nb190, with Lys-20 being more crucial than Tyr-23 for the
Rev-Nb190 interaction.
These results were confirmed in vitro by gel shift analysis for
Nb190 binding to the Rev mutants containing mutations in the
putative binding site. Gel shift experiments of the respective
alanine mutant Rev binding to the high affinity IIB hairpin of
RREwere performed in the presence of Nb190 (Fig. 4E). In vitro,
the Nb190-Rev interaction was completely abolished by the
K20A and Y23A mutations. Indeed, the addition of Nb190 to
IIB-RevK20A, IIB-RevY23A, or IIB-RevK20AY23A complexes did
not cause a reduction of the mobility, further confirming that
both Lys-20 andTyr-23 of Rev are critical residues for the bind-
ing of Nb190.
Nb190 Specifically Inhibits the Rev-dependent Expression of
RRE-containing RNA—To evaluate whether Nb190 influences
the Rev function in cells, we first analyzed its effect on the Rev-
dependent nucleocytoplasmic RNA export using the system
developed by Hope et al. (40). The pDM128CATRevRE plas-
mid produces an RRE-containing transcript that requires Rev
for expression of the CAT reporter. 293T cells were co-trans-
fected with pDM128CATRevRE and a Rev-producing plasmid,
resulting in the Rev-dependent expression of the CAT reporter
(Fig. 5A, left). Co-expression of Nb190 resulted in dose-depen-
dent reduction of Rev-dependent CAT production (Fig. 5A,
right).
To further determine whether the nanobody is specific for
the Rev-RRE-dependent RNA export, we compared the effect
of Nb190 on the RRE-dependent Gag expression with the
expression from the same vector in which the RRE was substi-
tuted by a constitutive transport element (Fig. 5, B and C). For
this experiment, we used the constitutive transport element
(CTE) from the Mason-Pfizer monkey virus (41). CTE-depen-
dent expression is Rev-independent (42, 43). Gag production
from pGag-RRE is greatly receptive to Rev (44) and inhibited by
Nb190 but not by theNb163 control, whereasNb190 had no effect
on Rev-independent CTE-driven expression of Gag.
Inhibition of the Rev Protein-Protein Interaction in Cells—
Next, the ability of Nb190 to inhibit Rev-Rev protein-protein
interactions in cells was investigated by testing the potency of
the nanobody to disrupt the RevM5-GFP/RevM10-BFP inter-
action in the nucleoli of HeLa cells. RevM5 is a mutant that is
unable to bind RNA (21) and localizes to the cytoplasm (Fig.
6A). RevM10 is a trans-dominant negative mutant that is not
exported to the cytoplasm and is found in the nucleoli of cells.
When RevM5-GFP and RevM10-BFP were co-expressed,
RevM5-GFP co-localized with RevM10-BFP in the nucleoli,
demonstrating an interaction between both proteins that holds
RevM5 in the nucleolus (Fig. 6A). We investigated whether
Nb190 can elicit the redistribution of M10-bound RevM5 from
the nucleolus to the cytoplasm. Therefore, we measured the
relative amount of RevM5-GFP found in the nucleoli of cells
that co-expressed RevM5-GFP, RevM10-BFP, andNb190-mKO
(Fig. 6B). This ratio was comparedwith that of cells co-express-
ing RevM5-GFP, RevM10-BFP, and the control Nb163-mKO.
Indeed, in cells expressing equal amounts of RevM10-BFP and
equal amounts of Nb-mKO, significantly less RevM5-GFP was
present in the nucleoli of the cells expressingNb190-mKO com-
pared with the cells expressing Nb163-mKO (Fig. 6B), suggest-
ing that Nb190-mKO disrupts the RevM5/RevM10 interaction,
allowing RevM5 to redistribute to the cytoplasm.
FIGURE 3. Nb190 interacts with Rev in cells. HeLa cells were transfected separately or co-transfected with expression plasmids as indicated. Subcellular
localization of the proteins was visualized by confocal fluorescence microscopy in both GFP and mKO channels. The right column shows overlay images. DIC,
differential interference contrast. Scale bar, 25 m.
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FIGURE 4. Rev residues Lys-20 and Tyr-23 form the binding epitope for Nb190. A and B, HeLa cells were co-transfected with expression plasmids as
indicated. Subcellular localization of the proteins was visualized by confocal fluorescencemicroscopy in both GFP andmKO channels. The right column shows
overlay images. Scale bar, 25m. C, fluorescence recovery after photobleaching of Nb190-mKOwhen bound to RevM10-BFP or RevM10 alaninemutants in the
nucleoli of cells is shown. The dashed circles indicate the photobleached area. Bleaching and recovery of Nb190-mKO in the nucleolusweremonitored for 540 s.
D, quantitative fluorescence recovery after photobleaching analysis of Nb190-mKO bound to RevM10 (blue) or RevM10 containing the single K20A (green) or
Y23A (red) mutation in the putative binding site. Values are averages from at least eight cells. E, the K20A and Y23Amutations disrupt the interaction between
Rev and Nb190 in vitro. Gel mobility shifts of labeled high affinity stem IIB RRE RNA in complex with Rev or Rev mutants were performed in the absence or
presence of Nb190, as indicated.wt, wild type.
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Rev-specific Inhibition of the HIV-1 Production—To assess
the potential of Nb190 for anti-HIV therapy, we investigated the
effects of Nb190 on HIV-1 expression. First, an Nb190 expres-
sion plasmid was co-transfected
together with the viral HIV-1NL4-3
molecular clone in 239T cells.
Transfection of cells with this
molecular clone recapitulates the
late events in the viral life cycle,
including Rev function, production
of all viralmRNAs and proteins, and
virus maturation. Virus production
was measured by analyzing the p24
Gag amount in the supernatants of
transfected cells. In contrast to
cells transfected with an expression
plasmid for the control nanobody
(Nb163), virus production was
markedly suppressed in a dose-de-
pendent manner in cells expressing
Nb190 (Fig. 7A). To confirm the
inhibitory effect of this nanobody
on viral production, we constructed
chimericHIV-1molecular clones by
inserting the nanobody coding
sequence in the nef open reading
frame (Fig. 7B). Such inserted unre-
lated genes are expressed by HIV-1
in place of Nef during virus replica-
tion. This set-up takes into account
the equal ratio of Rev versus nano-
body in the cells because they are
both expressed from multiply
spliced RNA in the same molecular
clone. These pNL-Nb chimeric
molecules were transfected in 293T
cells. Virus production from the
NL-Nb190 clone was reduced by
300-fold compared with the expres-
sion of wild-type NL4-3 or a control
virus expressing the control nano-
body Nb163 (Fig. 7B).
To confirm our inhibitor is inhib-
iting the HIV-1 production by spe-
cifically targeting the Rev function,
we assessed the effect of Nb190 on
the expression of a Rev-indepen-
dent HIV-1 molecular clone
NLRev()RRE()CTE() (42). In
this engineered infectious HIV-1
clone, Rev and RRE are substituted
by the CTE from the Mason-Pfizer
monkey virus. CTE-dependent ex-
pression is Rev-independent (43).
Upon co-transfection, Nb190 was
unable to reduce the expression of
this Rev-independent virus, rein-
forcing our conclusion that the
antiviral effect of this nanobody, targeting the N-terminal
-helical multimerization domain of Rev, closely correlates
with inhibition of the Rev function (Fig. 7C).
FIGURE 5.Nb190 specifically inhibits the Rev-dependent expression of RNA.A, Nb190 decreases the expres-
sion of RRE-containing RNAs in cells. Left, 293T cellswere transfectedwith pDM128CATRevRE in the absence or
presence of 1 g of Rev-expressing plasmid. As a control, the co-expression of RevM10 decreases the Rev-de-
pendent CAT expression. The transdominant negative RevM10 mutant disrupts export and expression of
Rev-dependent viral mRNAs (55). Right, Rev-dependent CAT expression in the presence of different amounts
(g) of nanobody-expressing plasmid as indicated. The graphs show the levels of the CAT reporter expression
as a percentage relative to the conditionwhere Revbut nonanobodywas added. Results aremean S.E. (error
bars) from four independent experiments. B andC, Nb190 inhibits the Rev-RRE- but not theCTE-dependentGag
expression. Left, 293T cellswere transfectedwith pGag-RRE or pGag-CTE in the absence or presence of Rev and
RevM10 encoding plasmid as indicated. Right, Rev-dependent Gag expression in the presence of different
amounts (g) of nanobody-expressing plasmid, as indicated. Results are mean S.E. (error bars), with n 4.
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Nb190 Inhibits the Expression of Late Viral RNAs—Compel-
ling independent confirmation of the Rev-specific effects of
Nb190 was obtained by analyzing its effect on the expression
levels of the different viral mRNA species. Wild-type HIV-1
produces three predominant size classes of viral mRNAs with
sizes of 9.3, 4, and 2 kb (45). The late unspliced 9.3-kb and
partially spliced 4-kb species are expressed in a Rev-dependent
manner, whereas the expression of the early multiply spliced
2-kb mRNAs is Rev-independent. In Northern blot (Fig. 8A)
and real-time quantitative reverse transcription-PCR experi-
ments (Fig. 8,B andC) on RNA extracted from cells transfected
with the chimeric NL-Nb190 molecular clone or co-transfected
with NL4-3 and Nb190, we found that the ratio of the late
unspliced transcripts over the early fully spliced mRNA was
greatly reduced compared with cells transfected with the wild-
type NL4-3 or the NL-Nb163 virus. These data establish that
Nb190 inhibits the HIV-1 production in cell culture by specifi-
cally disrupting Rev function.
DISCUSSION
In this study, we selected a nano-
body, derived from a llama heavy-
chain only antibody, that binds the
N-terminal -helical multimeriza-
tion domain of Rev and potently
inhibits its oligomerization. This
nanobody specifically suppresses
the Rev-dependent expression of
late viral RNAs. Previous attempts
to develop Rev antibodies have used
a single-chain antibody approach by
incorporating the variable regions
of light and heavy chains from a
conventional monoclonal antibody
in a single gene (SFv). These anti-
Rev SFv possess potent anti-HIV
activity by sequestering Rev to the
cytoplasm (46). The nanobody
described here also triggers a cyto-
plasmic relocalization of Rev, but in
contrast to the previously reported
anti-Rev SFv, it does not retain Rev
in the cytoplasm because Rev was
still able to shuttle between the
nucleus and cytoplasm in the pres-
ence of Nb190. We have demon-
strated that this nanobody binds
residues Lys-20 and Tyr-23 in the
N-terminal multimerization domain
of Rev, independently confirming
its anti-multimerization activity.
However, we cannot completely
exclude the possibility that, in addi-
tion to its anti-multimerization
effect, in cells the nanobody exerts
an extra anti-Rev activity that
involves the same or overlapping
Lys-20 and Tyr-23 residues. The N
terminus of Rev is essential for Rev
function and plays a role in its multimerization (17, 24, 25, 47).
TheDEADboxhelicaseDDX1 is a co-factor thatwas also found
to interact with the N terminus of Rev (48). Also, other DEAD
box helicases like DDX3 have an important role in Rev-depen-
dent HIV-1 gene expression (49). Future research will verify
whether in cells the nanobody, in addition to its anti-multim-
erization activity, also affects other functions. Nevertheless, by
identifying a new reactive site in the Rev protein, our findings
set the stage for the development of a novel class of anti-HIV
drugs.
The nanobody Nb190 identified here represents the first
knownmolecule that destabilizes and prevents the formation of
a large organized homoprotein complex required for efficient
HIV-1 mRNA export from the nucleus. Drugs directed against
this novel and highly specific viral target are not expected to
show any cross-resistance to all currently available clinically
used anti-HIV drugs. Given the vital and conserved role of Rev
FIGURE 6. Nb190 inhibits the interaction between RevM5-GFP and RevM10-BFP in the nucleoli of cells.
A, RevM5-GFP co-localizes with RevM10-BFP in cells. HeLa cells were transfected with expression plasmids, as
indicated, and localization of the proteins was visualized by confocal fluorescence microscopy. B, quantifica-
tion of the colocalization of RevM5-GFP with RevM10-BFP in the presence of Nb190-mKO or the control Nb163-
mKO. HeLa cells were co-transfected with RevM5-GFP, RevM10-BFP, and Nb190-mKO or Nb163-mKO and
imaged. Cells expressing equal amounts of RevM10-BFP in the nucleoli (BFPnucl) and equal amounts of mKO
(BFPtot), respectively, were analyzed for their amount of nucleolar RevM5-GFP (GFPnucl) versus total ReM5-GFP
over the cell (GFPtot). Results are mean S.E. (error bars), with n 50, p	 0.0005.
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in the HIV replication process, Rev inhibitors are also expected
to affect replication of a wide variety of HIV-1 strains. In HIV-
susceptible cells, this nanobody by itself may be used directly as
an effective anti-HIV agent in vivo using genetic immunization
strategies. Although the therapeutic potential of antibodies
aimed at intracellular targets may be questionable, our nano-
body provides a strong proof of principle that HIV-1 Rev, and
especially its residues Lys-20 and Tyr-23, is a potential target
for the development of therapeutic anti-HIV-1 agents. Indeed,
these residues are highly conserved: 92.7% for Lys-20 and 98.5%
for Tyr-23.Moreover, the Rev-Nb190 bindingmay be of value as
FIGURE 7. Nb190 efficiently inhibits the HIV-1 production. A, dose-depen-
dent inhibition of the HIV-1 production by the intracellular expression of
Nb190. 293T cells were co-transfected with the pNL4-3 molecular clone (0.5
g) and increasing amounts of the expression vector for Nb190 (red circles) or
the control nanobody Nb163 (green squares). A vector expressing the GFP
variant Dronpa was included as negative control (blue triangles). Production
of virus was analyzed by quantifying the virus-associated core antigen (Gag
p24) in the supernatants of the transfected cells. Values are expressed as
percentages relative to the p24 expression levels of cells transfected with
pNL4-3 only. Results aremean S.E. (error bars), with n 3. B, comparison of
NL4-3 and chimeric NL-Nb expression in cells.
Nb190 and Nb163 were cloned in the nef open reading frame of pNL4-3 (top),
and these chimeric molecular clones were transfected in 293T cells. The
amount of p24 in the supernatants of transfected cells was monitored as a
measure for HIV-1 expression (bottom). Results are mean  S.E. (error bars),
with n  4, p 	 0.0005. C, Nb190 fails to inhibit the viral production of a
Rev-independent molecular clone. 293T cells were transfected with
pNLRev()RRE()CTE() (0.5 g) and different amounts of Nb190, Nb163, or
Dronpa expression plasmids. Expression of pNLRev()RRE()CTE() was
analyzed bymeasuring the virus-associated core p24 antigen in the superna-
tants of the transfected cells. p24 production levels are presented relative to
control cells expressing pNL4-3Rev()RRE()CTE() only. Results are
mean S.E., with n 3.
FIGURE 8.Nb190 inhibits the expressionof partially spliced andunspliced
viral RNA. A, Northern blot analysis of viral mRNA species in cells transfected
with wild-type or chimeric pNL-Nb molecular clones. B and C, levels of late
unspliced relative to early multiply spliced viral mRNA species, as measured
by real-time quantitative reverse transcription-PCR. 293T cells were trans-
fected with wild-type or chimeric pNL-Nb clones (B) or co-transfected with
pNL4-3 and Dronpa control, Nb, or RevM10 vector plasmid, as indicated (C).
The difference in RNA sizes observed for the NL4-3 versus the chimeric NL-Nb
molecular clones is due to the insertion of the nanobody coding sequence in
the nef open reading frame for the chimeric viruses. Results are mean S.E.,
with n 3, p	 0.025.
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a tool for drug screening and as a starting point for drug design.
Indeed, by resolving the epitope, this nanobody represents a
suitable lead for antiviral drug development, and small mole-
cules may be modeled to interact with these residues. Progress
has been made in developing small molecules capable of dis-
rupting protein-protein interactions; however, this remains a
challenging but not impossible task (50). In particular, small
molecule inhibitors dissociating trimeric TNF- complexes or
the p53-HDM2 interaction have been described (50, 51). The
identification of this nanobody will also facilitate the establish-
ment of highly specific and sophisticated drug discovery meth-
ods both in vitro and in cells for the discovery of a new class of
inhibitors directed against this target.
Understanding the three-dimensional structure of Rev
would be advantageous for the rational design of small mole-
cules against this target. Although
circular dichroism, nuclear mag-
netic resonance, and Raman spec-
troscopy studies strongly suggest
that the oligomerization domains
and the nuclear localization signal
are components of a helix-turn-he-
lix motif (12–14), the full molecular
Rev structure is still unknown. This
is mainly because in solution Rev is
strongly prone to aggregation at
concentrations above 1 M, both in
the presence and in the absence of
RNA (52). Ultimately, blocking the
aggregation of Rev in solution by
nanobodiesmay be the key to unveil
its structure by x-ray crystallogra-
phy. Moreover, nanobodies have
proven potential as a crystallization
aid for structure determination of
proteins that present particular
experimental challenges and are not
conducive to more conventional
crystallization strategies (53).
This nanobody also proved a
powerful tool to study the mecha-
nism of Rev oligomer assembly and
allowed us to support a molecular
model for Rev assembly. Rev
includes two separate multimeriza-
tion domains that are joined, yield-
ing a head and tail protein surface
(24) (Fig. 9A). Two structural mod-
els for the Rev assembly along the
RRE are possible: a head-to-tail and
a head-to-head/tail-to-tail configu-
ration. Nanobodies that selectively
bind the head or the tail of themon-
omer can distinguish these two sce-
narios as outlined in Fig. 9B. Accu-
mulation of monomeric Rev in the
presence of nanobody would indi-
cate a head-to-tail configuration
(Fig. 9B, right), whereas accumulation of Rev dimers would
favor the model of symmetrical head-to-head and tail-to-tail
multimer formation (Fig. 9B, left). We consistently observed
that Nb190 fails to completely eliminate the FRET signal in the
in vitro multimerization assay, whereas purified recombinant
Rev completely reduces the FRET signal to background levels.
We speculate that the residual FRET signal in the presence of
Nb190 results from ECFP-Rev/EYFP-Rev dimers. Indeed, in gel
shift experiments, the presence of Nb190 reduced the amounts
of multimeric Rev-RRE complexes and concomitantly led to the
accumulation of dimeric Rev species. The observed accumula-
tion of dimeric Rev upon inhibition of multimerization pro-
vides independent support for a head-to-head/tail-to-tail
model for Rev assembly (24) (Fig. 9B, left). In addition, alanine
scan mutations revealed that Nb190 is binding to Rev residues
FIGURE 9.Model for inhibition of Revmultimerization. A, helical wheel projectionmodel of a Revmonomer
molecule (adapted from Ref. 24). Protein residues implicated in multimerization are indicated in blue for the
head surface and in green for the tail surface. Residues Lys-20 and Tyr-23, important for nanobody binding, are
indicated in red. B, structural model for Rev multimeric assembly of Rev on the RRE and inhibition by Nb190.
Possible models for Rev multimerization are shown: the head-to-head/tail-to-tail model for Rev multimeriza-
tion, which is supported by our data (left), and head-to-tail model (right).
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Lys-20 and Tyr-23, which are, according to the latest structural
models for Rev, located within the -helical surface that con-
tributes to the head multimerization facade of Rev (24) (Fig.
9A). This result obtained both in vitro and in physiological con-
ditions, confirms the anti-multimerization effect of the nano-
body and indicates that Nb190 selectively binds the head surface
of Rev. Moreover, recent single molecule experiments have
indicated that the assembly of Rev on RRE proceeds stepwise
after nucleation of a single Revmonomer bound to a high affin-
ity site in stem-loop IIB (27). These findings, together with our
observation that Nb190 interacts with the headmultimerization
surface, suggests that the first Revmolecule is positioned on the
RRE in such a way that the second monomer binds through a
tail-to-tail interaction (Fig. 9B, left).
Assembly of a functional multimeric Rev-RRE ribonucleo-
protein complex requires themultimerization of Rev ontomul-
tiple specific RNA sites. Rev shows a cooperative chameleon-
like RNA binding behavior, implying that it employs different
surfaces of its RNA-binding domain to recognize different low
affinity binding sites on the RRE (26, 54). Our data show that
inhibition of the oligomerization at the stage of the first dimer
formed on the RRE prevents the further coating of the RNA
(Fig. 2B). These data confirm that the oligomeric assembly of
Rev follows an ordered stepwise process that starts at a single
site on the RRE.
In conclusion, by selecting a nanobody that targets the Rev
N-terminal -helical multimerization domain and blocks the
oligomerization of Rev, we have identified a reactive site in the
Rev protein that will inspire future novel approaches for thera-
peutic intervention against HIV. The nanobody also proved to
be a unique tool to refine the molecular model for concerted
assembly of Rev multimers to a stepwise head-to-head/tail-to-
tail mechanism. Furthermore, it is a valuable instrument to
further unravel in cells the complex pathway of HIV mRNA
nucleocytoplasmic transport and the interplay with cellular
co-factors.
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